(redirected from Vitrase)
Also found in: Thesaurus, Medical, Encyclopedia.


 (hī′ə-lo͝o-rŏn′ĭ-dās′, -dāz′)
An enzyme that catalyzes the breakdown of hyaluronic acid in the body, thereby increasing tissue permeability to fluids. Also called spreading factor.


(ˌhaɪəlʊˈrɒnɪˌdeɪs; -ˌdeɪz)
(Biochemistry) an enzyme that breaks down hyaluronic acid, thus decreasing the viscosity of the medium containing the acid
[C20: hyalo- + Greek ouron urine + -id3 + -ase]


(ˌhaɪ ə lʊˈrɒn ɪˌdeɪs, -ˌdeɪz)

an enzyme that decreases viscosity in the tissue spaces of the body by breaking down hyaluronic acid: used as an ingredient for diffusing injected drugs.
[1935–40; hyaluron(ic acid) + -id- + -ase]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.hyaluronidase - an enzyme (trade name Hyazyme) that splits hyaluronic acid and so lowers its viscosity and increases the permeability of connective tissue and the absorption of fluids
enzyme - any of several complex proteins that are produced by cells and act as catalysts in specific biochemical reactions
References in periodicals archive ?
Every drug the compounders supply cuts in to the business of companies like those making Hylenex and Vitrase.
47-48) Vitrase is an approved product using an ovine source of hyaluronidase.
Vitrase, on the other hand, is a formulation of hyaluronidase extracted from ovine (ram) testicles.
Shares in the company have slumped worryingly since the announcement this week that the conclusion of the third phase of the clinical trials on the Vitrase drug in the US had been postponed.
Vitrase is an injectable drug designed to induce the clearing of vitreous hemorrhage, or bleeding into the back portion of the eye, in less time than is normally required for clearing to occur on its own so that the ophthalmologist can treat the underlying problem.
s) Termination of ISTA Vitrase collaboration agreement (including interest income of $0.
ISTA's four prescription products, BROMDAY(TM), BEPREVE, ISTALOL, and VITRASE, will complement Bausch + Lomb's existing prescription ophthalmology products, including Lotemax and Besivance, and branded OTC eye vitamins PreserVision and Ocuvite.
7 million (k) Restructuring charge and related inventory write-offs (l) Transition/duplicate operating expenses (m) ISTA Vitrase collaboration fee (n) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions): Tax effect Non-GAAP pre-tax adjustments of $34.
3 million (h) Transition/duplicate operating expenses (i) ISTA Vitrase collaboration fee (j) Tax effect for non-GAAP adjustments "GAAP" refers to financial information presented in accordance with generally accepted accounting principles in the United States.
Net revenue growth was driven primarily by strong demand for XIBROM(TM) and BEPREVE, supported by revenue increases in VITRASE.